These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
227 related items for PubMed ID: 12879693
1. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation]. Basić-Jukić N, Labar B. Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693 [Abstract] [Full Text] [Related]
2. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. Imado T, Iwasaki T, Kuroiwa T, Sano H, Hara H. Transplantation; 2004 Feb 15; 77(3):391-8. PubMed ID: 14966413 [Abstract] [Full Text] [Related]
3. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Margolis J, Vogelsang G. Semin Oncol; 2000 Apr 15; 27(2 Suppl 5):72-7. PubMed ID: 10877057 [Abstract] [Full Text] [Related]
4. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)]. Ji SQ, Chen HR, Wang HX, Yan HM, Liu J, Xue M, Zhu L. Zhonghua Xue Ye Xue Za Zhi; 2003 Aug 15; 24(8):416-9. PubMed ID: 14642179 [Abstract] [Full Text] [Related]
5. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. Yang I, Weiss L, Abdul-Hai A, Kasir J, Reich S, Slavin S. Cancer Res; 2005 Nov 01; 65(21):9735-40. PubMed ID: 16266994 [Abstract] [Full Text] [Related]
6. Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Hess AD. Biol Blood Marrow Transplant; 2006 Jan 01; 12(1 Suppl 2):13-21. PubMed ID: 16399597 [Abstract] [Full Text] [Related]
7. [Eradication of adult T-cell leukemia cells and maintenance of remission by the graft-versus-leukemia effect after allogeneic bone marrow transplantation]. Ota K, Hashino S, Shimizu K, Yonezumi M, Chiba K, Kondo T, Suzuki S, Imamura M, Asaka M. Rinsho Ketsueki; 2004 Sep 01; 45(9):1044-7. PubMed ID: 15510833 [Abstract] [Full Text] [Related]
8. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Prigozhina TB, Elkin G, Khitrin S, Slavin S. Exp Hematol; 2008 Dec 01; 36(12):1750-9. PubMed ID: 18809241 [Abstract] [Full Text] [Related]
9. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS. Nat Med; 2003 Sep 01; 9(9):1144-50. PubMed ID: 12925844 [Abstract] [Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL. Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527 [Abstract] [Full Text] [Related]
11. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH. Biol Blood Marrow Transplant; 2004 May 01; 10(5):328-36. PubMed ID: 15111932 [Abstract] [Full Text] [Related]
12. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Lazarus HM, Vogelsang GB, Rowe JM. Bone Marrow Transplant; 1997 Mar 01; 19(6):577-600. PubMed ID: 9085738 [Abstract] [Full Text] [Related]
13. Drug therapy for acute graft-versus-host disease prophylaxis. Simpson D. J Hematother Stem Cell Res; 2000 Jun 01; 9(3):317-25. PubMed ID: 10894353 [Abstract] [Full Text] [Related]
14. Treatment of GVHD after blood transfusion. Sakuma H, Kikuta A, Suzuki H. Fukushima J Med Sci; 1993 Dec 01; 39(2):113-6. PubMed ID: 7927134 [Abstract] [Full Text] [Related]
15. MC1288, a vitamin D analog, prevents acute graft-versus-host disease in rat bone marrow transplantation. Pakkala I, Taskinen E, Pakkala S, Räisänen-Sokolowski A. Bone Marrow Transplant; 2001 Apr 01; 27(8):863-7. PubMed ID: 11477445 [Abstract] [Full Text] [Related]
16. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA. Biol Blood Marrow Transplant; 2007 Dec 01; 13(12):1487-98. PubMed ID: 18022579 [Abstract] [Full Text] [Related]
18. Atypical acute graft-versus-host disease. Shin J, Hong W, Song H, Choi G, Kim YC. Am J Dermatopathol; 2007 Dec 01; 29(6):576-7. PubMed ID: 18032957 [Abstract] [Full Text] [Related]
19. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. Oliveira JS, Bahia D, Franco M, Balda C, Stella S, Kerbauy J. Bone Marrow Transplant; 1999 Jan 01; 23(1):99-101. PubMed ID: 10037059 [Abstract] [Full Text] [Related]
20. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Karwacka E, Ołdakowska-Jedynak U, Brydak-Godowska J, Paczek L, Kecik D. Transplant Proc; 2006 Jan 01; 38(1):292-4. PubMed ID: 16504728 [Abstract] [Full Text] [Related] Page: [Next] [New Search]